Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline Plus Carvedilol in Decompensated Cirrhosis
NCT06041932Unknown
- Sponsor
- Institute of Liver and Biliary Sciences
- Start
- Nov 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pentoxifylline in Liver cirrhosis (LC) (2 arms), sponsored by Institute of Liver and Biliary Sciences. Primary endpoint: Incidence of New onset clinical decompensation at 1 year. Status: unknown.
02
Drugs
pentoxifylline
03
Conditions
Liver cirrhosis (LC)
Beyond the preview
Go deeper on NCT06041932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06041932.